Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomed, Double-blind Efficacy and Safety Comparing SAR442168 and Terfluramide (Aubaglo) in Particpants With Relapsing Forms of Multiple Sclerosis (GEMINI1)

Next Previous
Trial Profile

A Phase 3, Randomed, Double-blind Efficacy and Safety Comparing SAR442168 and Terfluramide (Aubaglo) in Particpants With Relapsing Forms of Multiple Sclerosis (GEMINI1)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 02 Sep 2024 According to a Sanofi media release, results from this trial will be presented at the ECTRIMS medical meeting, September 20.
  • 02 Sep 2024 Primary endpoint has not been met. (annualized adjudicated relapse rate (ARR)), according to a Sanofi media release.
  • 21 Jul 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top